ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture
Contract development and manufacturing organisation ViroCell Biologics has partnered AvenCell Therapeutics for expediting the development of new allogeneic chimeric antigen…
Oncology
-
-
Sanofi’s Sarclisa gains EC approval for multiple myeloma treatment
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone…
-
Hengrui Pharma and GSK link across key therapeutic areas
Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic…
-
Pfizer and 3SBio conclude licensing deal for SSGJ-707
Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the development, production…
-
GSK’s Blenrep combos approved for multiple myeloma in EU
GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple…
-
Janssen’s Darzalex new indication gains EC approval for SMM
The European Commission (EC) has approved the Johnson & Johnson company Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) subcutaneous…
-
GSK’s Blenrep faces setback as FDA cancer committee votes against approval
The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab…
-
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing…
-
EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma
BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with gemcitabine and…
-
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, a cluster of…
